Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and paclitaxel) on patients with relapsed ovarian, fallopian or primary peritoneal carcinoma. Recently the investigators have found that the combination of decitabine and selinexor, two Food and Drug Administration (FDA) approved chemotherapy agents, may prevent or reverse the development of drug resistance and further the remissions and duration of remissions with standard ovarian cancer chemotherapy with carboplatin and

Trial Details

NCT ID
NCT05983276
Phase
PHASE2
Sponsor
Loyola University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Decitabine
  • Carboplatin
  • Paclitaxel
  • Selinexor
Locations (sample)
  • Maywood, Illinois, United States|41.8792,-87.84312

Key Eligibility Criteria

  • Participants must be greater than or equal to 18 years of age
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status PS less than or equal to 2.
  • Participants must have histological or cytological proven epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma with relapse or…
  • Participants must have failed or relapsed after a platinum and taxane containing combination

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →